A new version of Evo, the AI developed at the Arc Institute that can be used to design genomes as long as that of a bacterium, has been retrained with the DNA sequences of three domains of life – viruses, bacteria and eukaryotes. Read More
Aptamers are single-stranded DNA or RNA molecules with unique 3D structures that allow for specific binding to a wide variety of ions and molecules. Due to their unique properties, aptamers have been extensively studied for the precise detection and treatment of cancer; however, their susceptibility to nuclease degradation and rapid renal clearance represent challenges that limit theranostic time window and effectiveness. Researchers from Huazhong University of Science and Technology evaluated the potential of a novel albumin-conjugation strategy that would improve tumor targeting of the aptamers. Read More
Thetis Pharmaceuticals LLC has presented preclinical data on their BLT1 receptor agonist TP-317 as an approach for treating inflammatory bowel disease. BLT1 activation promotes immune homeostasis and repair; oral therapy with TP-317 was investigated in two preclinical models of colitis and ileitis. Read More
Photys Therapeutics Inc. has signed a license agreement with Hangzhou Polymed Biopharmaceuticals Inc. for HPB-143, a phase I-ready IRAK-4 degrader. IRAK-4 degradation offers potential to treat various autoimmune indications, including atopic dermatitis and hidradenitis suppurativa. Read More
Researchers from MBX Biosciences Inc. presented preclinical data on MBX-4291, a prodrug developed as a long-acting GLP-1/GIP co-agonist through MBX’s proprietary Precision Endocrine Peptide (PEP) platform. Read More
The Clarivate Medtech Trends to Watch in 2024 report noted the resilience of the medtech sector in the face of changing macroeconomic factors and the preparation required to navigate the market’s many complexities. It is likely that 2025 will be no different. Read More
Targeted protein degradation (TPD) is an alternative to conventional protein inhibition that is gaining attention due to advantages such as ensuring complete elimination of the target protein, reduced off-target effects or the potential to target previously inaccessible or “undruggable” proteins. Proteolysis targeting chimeras (PROTACs) are agents used for TPD that have proven effective for degradation of histone deacetylase (HDAC), among other different proteins. Read More
Anterior gradient 2 (AGR2) is a protein located in the endoplasmic reticulum involved in protein folding and when stressed, it is secreted into the extracellular space and it attracts monocytes, activates fibroblasts and disrupts the epithelial integrity. The relationship between the expression of AGR2 in tissues from patients with inflammatory bowel disease (IBD) was investigated, as well as the efficacy of an anti-AGR2 antibody in murine models of colon inflammation and fibrosis. Read More
Adcentrx Therapeutics Inc. and Adcentrx Therapeutics Shanghai Co. Ltd. have disclosed antibody-drug conjugates comprising a monoclonal antibody covalently bound to a cytotoxic drug through a linker. Read More
Beijing Earthwise Technology Co. Ltd. has synthesized E3 ubiquitin-protein ligase CBL-B inhibitors reported to be useful for the treatment of cancer. Read More
Researchers from Columbia University Irving Medical Center and collaborators applied unbiased scRNA-seq to study Lepr expression in lung mesenchymal cells. To do that, they used a Lepr(creERT2) mouse model tracing LEPR+ alveolar fibroblasts during neonatal alveologenesis. Read More
Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have identified glucagon-like peptide 1 receptor (GLP-1R) agonists reported to be useful for the treatment of diabetes, obesity and nonalcoholic or metabolic dysfunction-associated steatohepatitis (NASH/MASH). Read More
Duke Street Bio Ltd. has divulged poly(ADP-ribose) polymerase 1 (PARP-1; ARTD1) inhibitors reported to be useful for the treatment of cancer. Read More
Ubiquitin-specific protease 7 (USP7) is involved in DNA repair and cell cycle progression and, due to its control over the ubiquitination of key proteins, may impact oncogenes like MDM2 and c-Myc, as well as tumor suppressors such as p53 and p21. Read More
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co. Ltd. has described glucagon-like peptide 1 receptor (GLP-1R) agonists reported to be useful for the treatment of diabetes, obesity, Alzheimer’s disease, overweight and nonalcoholic or metabolic dysfunction-associated steatohepatitis (NASH/MASH). Read More
